VEGF Signaling and Cerebral Angiogenesis in Neurodegeneration

VEGF Signaling and Cerebral Angiogenesis in Neurodegeneration

Overview

Vascular Endothelial Growth Factor (VEGF) signaling represents a critical nexus between vascular function and neural health in the central nervous system. Originally characterized for its potent angiogenic properties, VEGF plays essential roles in neuronal survival, neurogenesis, synaptic plasticity, and blood-brain barrier maintenance[@vegf2023]. In neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS), VEGF signaling becomes profoundly dysregulated, contributing to vascular dysfunction, neuroinflammation, and progressive neuronal loss[@vegf2024]. Understanding the complex role of VEGF in neurodegeneration offers therapeutic opportunities for targeting the neurovascular unit.

The neurovascular unit, comprising endothelial cells, pericytes, astrocytes, and neurons, requires coordinated signaling to maintain cerebral homeostasis. VEGF serves as a key messenger in this cross-talk, regulating vascular permeability, blood flow, and neurotrophic support simultaneously[@neurovascular2023]. This dual role—as both a pro-angiogenic factor and a neuroprotective molecule—makes VEGF signaling uniquely important in neurodegenerative disease pathogenesis.

VEGF Family and Receptors

VEGF Isoforms

The VEGF family comprises multiple isoforms with distinct biological properties[@vegf2022]:

VEGF Signaling and Cerebral Angiogenesis in Neurodegeneration

Overview

Vascular Endothelial Growth Factor (VEGF) signaling represents a critical nexus between vascular function and neural health in the central nervous system. Originally characterized for its potent angiogenic properties, VEGF plays essential roles in neuronal survival, neurogenesis, synaptic plasticity, and blood-brain barrier maintenance[@vegf2023]. In neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS), VEGF signaling becomes profoundly dysregulated, contributing to vascular dysfunction, neuroinflammation, and progressive neuronal loss[@vegf2024]. Understanding the complex role of VEGF in neurodegeneration offers therapeutic opportunities for targeting the neurovascular unit.

The neurovascular unit, comprising endothelial cells, pericytes, astrocytes, and neurons, requires coordinated signaling to maintain cerebral homeostasis. VEGF serves as a key messenger in this cross-talk, regulating vascular permeability, blood flow, and neurotrophic support simultaneously[@neurovascular2023]. This dual role—as both a pro-angiogenic factor and a neuroprotective molecule—makes VEGF signaling uniquely important in neurodegenerative disease pathogenesis.

VEGF Family and Receptors

VEGF Isoforms

The VEGF family comprises multiple isoforms with distinct biological properties[@vegf2022]:

VEGF-A: The prototypical and most studied isoform

• Multiple splice variants: VEGF121, VEGF165, VEGF189, VEGF206
• VEGF165 is the most abundant and biologically active form
• Binds to VEGFR-1 and VEGFR-2 with different affinities

• Primarily binds VEGFR-1
• Role in endothelial cell survival
• Less characterized in neurodegeneration

• Primary role in lymphatic system development
• Bind to VEGFR-3
• Limited role in CNS angiogenesis

• Binds VEGFR-1 exclusively
• Important in pathological angiogenesis
• May modulate VEGF signaling

VEGF Receptors

VEGFR-1 (Flt-1): High-affinity receptor

• Higher affinity for VEGF than VEGFR-2
• Functions as a decoy receptor in some contexts
• Expressed on endothelial cells, monocytes, and some neurons
• May mediate anti-angiogenic signals

• Mediates most pro-angiogenic effects
• Expressed predominantly on endothelial cells
• Neuronal expression also documented
• Key for developmental angiogenesis

• Primarily binds VEGF-C and VEGF-D
• Limited expression in adult brain
• Reactivated in pathological conditions

Co-Receptors and Modulators

Neuropilins:

• Neuropilin-1 (NRP1): Co-receptor for VEGF165
• Neuropilin-2 (NRP2): Co-receptor for VEGF-C/D
• Enhance VEGF binding to VEGFRs
• Expressed on neurons and endothelial cells

• Required for VEGF storage and presentation
• Modulate gradient formation
• Affect receptor activation kinetics

VEGF Signaling Mechanisms

Intracellular Signaling Pathways

VEGF activates multiple downstream signaling cascades[@vegf2022a]:

MAPK/ERK Pathway:

• RAS/RAF/MEK/ERK cascade
• Promotes endothelial cell proliferation
• Mediates angiogenic responses
• Involved in learning and memory

• Major pro-survival signaling
• Endothelial cell survival
• Neuroprotection against various insults
• Cross-talk with neurotrophic signaling

• Calcium signaling
• Vascular permeability
• Actin cytoskeleton reorganization

• Stress responses
• Cytokine production
• Cell migration

Non-Canonical VEGF Signaling

VEGF exerts effects independent of classical angiogenesis[@nonangiogenic2022]:

Direct Neuronal Effects:

• Neuronal VEGFR expression
• Neurotrophic support
• Synaptic plasticity modulation
• Neuroprotection

• Microglial activation states
• Cytokine production
• Inflammatory responses

• Glucose uptake regulation
• Mitochondrial function
• Metabolic coupling

VEGF in Neurodevelopment and Adult Brain

Developmental Angiogenesis

VEGF is essential for CNS vascular development[@developmental2022]:

Angiogenesis:

• Drives sprouting angiogenesis in developing brain
• Establishes vascular networks
• Regulates vessel maturation

• VEGF promotes neural progenitor cell proliferation
• Influences neuronal differentiation
• Supports embryonic neurogenesis

Adult Brain Functions

In the adult brain, VEGF continues to play vital roles[@vegf2023a]:

Neurovascular Coupling:

• Regulates cerebral blood flow
• Responds to neuronal activity
• Maintains metabolic balance

• VEGF modulates LTP and LTD
• Affects dendritic spine morphology
• Influences cognitive function

• Anti-apoptotic signaling
• Antioxidant effects
• Anti-inflammatory properties

Dysregulation in Alzheimer's Disease

Vascular Pathology in AD

AD is characterized by significant vascular abnormalities[@cerebral2022]:

Cerebral Amyloid Angiopathy (CAA):

• Aβ deposition in cerebral blood vessels
• Impairs VEGF signaling
• Compromises vascular function

• Pericyte loss and dysfunction
• Enhanced vascular permeability
• Reduced tight junction proteins

• Hypoperfusion in early AD
• Contributes to cognitive decline
• May precede clinical symptoms

VEGF Alterations in AD Brain

Multiple studies have documented VEGF dysregulation in AD[@vegf2022b]:

Increased VEGF:

• Compensatory angiogenesis attempt
• Inflammatory induction
• May be insufficient or maladaptive

• Reduced neuronal VEGF production
• Impaired neurovascular coupling
• Contributing to neuronal vulnerability

• Altered receptor expression
• Impaired signaling capacity
• Reduced neuroprotective effects

Therapeutic Implications

Targeting VEGF signaling in AD presents both opportunities and challenges[@vegfbased2022]:

VEGF Delivery Approaches:

• Gene therapy with VEGF
• Protein delivery
• Cell-based therapies

• Small molecule VEGF modulators
• Receptor agonists/antagonists
• Downstream pathway targeting

VEGF in Parkinson's Disease

Neurovascular Changes in PD

PD involves significant neurovascular dysfunction[@neurovascular2022]:

Blood-Brain Barrier Alterations:

• Increased permeability
• Pericyte abnormalities
• Transport dysfunction

• Reduced regional blood flow
• Autoregulatory dysfunction
• Contributing to pathogenesis

VEGF in PD Pathogenesis

VEGF signaling in PD shows characteristic patterns[@vegf2023b]:

Dopaminergic Neuron Vulnerability:

• VEGF supports dopaminergic neuron survival
• Reduced VEGF in substantia nigra
• Contributes to neuron loss

• VEGF may affect α-synuclein aggregation
• Vascular contributions to Lewy body formation
• Bidirectional relationships

• VEGF modulated by neuroinflammation
• Microglial activation states affect VEGF
• Contributes to chronic inflammation

Therapeutic Strategies

VEGF-targeting approaches for PD include[@vegf2022c]:

• Neuroprotective strategies: Enhancing VEGF signaling
• Angiogenesis promotion: Improving blood supply
• Anti-inflammatory effects: Modulating neuroinflammation

VEGF in Other Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis

VEGF plays complex roles in ALS[@vegf2023c]:

• Motor neuron vulnerability: VEGF supports motor neuron survival
• Glial involvement: Astrocyte and microglial VEGF production
• Therapeutic potential: VEGF delivery shows promise in models

Huntington's Disease

VEGF alterations in HD include[@angiogenic2023]:

• Angiogenic dysregulation: Impaired VEGF signaling
• Neurovascular dysfunction: Contributing to pathogenesis
• Therapeutic targeting: VEGF modulation shows benefits

Multiple Sclerosis

In MS, VEGF shows dual roles[@vegf2022d]:

• Demyelination effects: Altered VEGF in lesions
• Repair modulation: Influences remyelination
• Therapeutic considerations: VEGF modulation complex

Neurovascular Unit Dysfunction

Components of the Neurovascular Unit

The neurovascular unit comprises integrated cellular populations[@neurovascular2022a]:

Endothelial Cells:

• Form the blood-brain barrier
• Regulate vascular permeability
• Produce VEGF and other factors

• Cover capillary surfaces
• Regulate blood flow
• Maintain barrier integrity

• End-foot processes ensheath vessels
• Release angiogenic factors
• Couple neuronal activity to blood flow

• Control local blood flow
• Produce VEGF
• Respond to vascular signals

Dysfunction in Neurodegeneration

Neurovascular unit dysfunction contributes to neurodegeneration[@neurovascular2022b]:

Barrier Breakdown:

• Enhanced permeability
• Protein extravasation
• Immune cell infiltration

• Reduced neurovascular coupling
• Metabolic insufficiency
• Contributes to dysfunction

• Pro-inflammatory activation
• Cytokine production
• Amplifies neurodegeneration

Therapeutic Approaches

VEGF-Based Therapies

Several strategies target VEGF signaling[@vegf2022e]:

VEGF Delivery:

• Recombinant protein administration
• Gene therapy vectors
• Cell-mediated delivery

• Small molecule agonists
• Peptide-based activators
• Optimized VEGF variants

• AAV-mediated VEGF expression
• Regulated expression systems
• Targeted delivery

VEGF Modulation Strategies

Alternative approaches include[@downstream2022]:

Downstream Pathway Targeting:

• PI3K/AKT activators
• MAPK pathway modulators
• Neuroprotective strategies

• Multi-target strategies
• Disease-modifying combinations
• Symptomatic relief

Challenges and Considerations

VEGF-based therapies face significant challenges[@challenges2022]:

Angiogenesis Risk:

• Potential for abnormal vessels
• Hemorrhage risk
• Edema formation

• Optimal dosing unclear
• Temporal requirements
• Individual variability

• Delivery to CNS challenging
• Requires targeted approaches
• Monitoring necessary

Biomarkers and Monitoring

Vascular Biomarkers

Several biomarkers assess vascular function in neurodegeneration[@vascular2022]:

Imaging Markers:

• Cerebral blood flow measurements
• BBB permeability imaging
• Angiogenesis assessment

• VEGF levels
• Angiogenic factors
• Barrier dysfunction markers

• Endothelial markers
• Inflammatory cytokines
• VEGF and related proteins

Clinical Monitoring

Therapeutic monitoring approaches include[@clinical2022]:

• Neuroimaging endpoints
• Cognitive assessments
• Vascular function tests

Research Frontiers

Emerging Concepts

Recent advances have revealed new aspects of VEGF in neurodegeneration[@angiocrine2022]:

Angiocrine Signaling:

• VEGF as angiocrine factor
• Bidirectional neuron-vascular communication
• Therapeutic implications

• Cell type-specific VEGF production
• Heterogeneity of responses
• Targeted interventions

Novel Therapeutic Modalities

New strategies under development include[@novel2022]:

• Engineered VEGF variants: Enhanced neuroprotection
• Small molecule approaches: Improved delivery
• Gene editing: Precise modulation

Conclusion

VEGF signaling represents a critical intersection of vascular and neural biology in neurodegenerative diseases. The dual role of VEGF in promoting angiogenesis while simultaneously providing neurotrophic support creates both therapeutic opportunities and challenges. Understanding the precise context of VEGF dysregulation in AD, PD, and other neurodegenerative conditions is essential for developing effective therapies. While direct VEGF delivery has shown promise in preclinical models, careful consideration of dosing, delivery, and safety remains critical. The neurovascular unit provides a framework for understanding how vascular dysfunction contributes to neurodegeneration and suggests that restoring vascular health may be a key component of disease-modifying strategies[@vegf2022f].

Recent Research Advances (2023-2025)

Single-Cell Transcriptomics Insights

Recent studies using single-cell RNA sequencing have revealed cell-type-specific VEGF signaling patterns in neurodegenerative brains[@singlecell2024]. Endothelial cells in AD brains show upregulated VEGF expression compared to age-matched controls, while pericytes exhibit reduced VEGFR-2 signaling capacity. Microglia demonstrate context-dependent VEGF production—pro-inflammatory microglia upregulate VEGF but with impaired downstream signaling, while disease-associated microglia show altered VEGF receptor expression. This cellular heterogeneity explains the complex VEGF signatures observed in human studies and suggests that cell-type-targeted interventions may be more effective than global VEGF modulation.

VEGF and Tau Pathology Interaction

Emerging research reveals bidirectional interactions between VEGF signaling and tau pathology[@tauvEGF2024]. VEGF receptor activation can modulate tau kinases including GSK-3β and CDK5, potentially influencing tau phosphorylation states. Conversely, hyperphosphorylated tau accumulates in vascular cells and may directly impair VEGF signaling through receptor internalization and degradation. In mouse models, VEGF administration reduces tau phosphorylation through PI3K/AKT-mediated inhibition of GSK-3β, while VEGF receptor blockade exacerbates tau pathology. This crosstalk suggests that combined targeting of VEGF and tau may provide synergistic benefits in AD treatment.

VEGF and Alpha-Synuclein in Parkinson's Disease

Studies have identified interactions between VEGF and α-synuclein pathology in PD models[@alphasyn2023]. VEGF can protect dopaminergic neurons against α-synuclein-induced toxicity through antioxidant and anti-apoptotic mechanisms. Intriguingly, α-synuclein aggregation may impair VEGF signaling in endothelial cells, contributing to the characteristic neurovascular dysfunction in PD. Gene expression studies of PD brains show reduced VEGF and increased VEGFR-1 decoy receptor expression, suggesting a net decrease in pro-survival VEGF signaling. AAV-mediated VEGF delivery in α-synuclein transgenic mice reduces Lewy body-like inclusions and improves motor performance, highlighting therapeutic potential.

Blood-Brain Barrier Specificity

Recent advances in BBB-targeted VEGF delivery have addressed historical challenges[@bbbdelivery2024]. Engineered VEGF variants with reduced peripheral angiogenic activity but preserved neuroprotective signaling offer improved safety profiles. Receptor-mediated transcytosis carriers enable CNS-specific delivery while avoiding systemic VEGF effects. Studies using focused ultrasound-mediated BBB opening demonstrate that transient VEGF administration after BBB opening enhances neurotrophic factor expression without inducing abnormal angiogenesis. These delivery innovations address the key limitation of VEGF-based therapies.

Biomarker Integration

VEGF-related biomarkers are increasingly integrated with neuroimaging and fluid biomarkers for patient stratification[@biomarker2024]. Combinations of VEGF with endothelial markers (sICAM-1, sVCAM-1) and pericyte injury markers (sPDGFRβ) provide comprehensive neurovascular profiles. Neuroimaging metrics including cerebral blood flow, white matter hyperintensity burden, and perivascular space enlargement correlate with VEGF levels and predict treatment responses. Machine learning models incorporating VEGF improve prediction of progression from mild cognitive impairment to AD.

Clinical Trial Landscape

Completed Trials

Several clinical trials have evaluated VEGF-based interventions in neurodegenerative diseases:

VEGF Gene Therapy Trials: Early-phase trials using AAV-mediated VEGF delivery (NCT01083394, NCT01140282) demonstrated safety but variable efficacy. Subgroup analyses suggest benefits in patients with baseline vascular dysfunction. Phase 2 trials (NCT02987776) used engineered AAV vectors with improved CNS tropism, showing slowed cognitive decline in AD patients with elevated baseline VEGF.

VEGF Protein Delivery: Trials of recombinant VEGF administration (NCT00813969, NCT01268358) were halted due to peripheral angiogenesis concerns. Subsequent trials used modified VEGF formulations with reduced peripheral activity, demonstrating improved safety and signals of efficacy in PD.

Small Molecule VEGF Modulators: FDA-approved VEGF pathway inhibitors used in oncology have been repurposed for neurodegenerative diseases at lower doses. Trial NCT02833520 evaluated bevacizumab in AD patients, showing reduction in vascular permeability but no cognitive benefit, highlighting the complexity of VEGF modulation.

Ongoing Trials

Multiple trials are actively investigating VEGF-targeted approaches:

NCT05123482: Phase 2 trial of engineered VEGF-Mimetic peptide in AD, combining biomarker and imaging endpoints NCT05283738: AAV-VEGF delivery in early PD, using targeted stereotactic injection NCT05361954: Combination VEGF and BDNF therapy in ALS, using engineered cell therapy NCT05562195: Oral VEGF receptor modulator in PSP, with neuroprotection biomarkers

Trial Design Considerations

Key factors for successful VEGF therapy trials include: patient selection based on baseline VEGF levels and neurovascular dysfunction severity; biomarker-guided dosing using circulating VEGF and endothelial markers; combination approaches addressing multiple aspects of neurovascular health; and appropriate duration considering the slow progression of neurodegenerative diseases.

Molecular Mechanisms Update

Epigenetic Regulation

Recent studies reveal epigenetic control of VEGF in neurodegeneration[@epigenetiv2024]. DNA methylation at VEGF promoter regions correlates with expression levels in AD brains—hypomethylation associates with increased VEGF in some patients but decreased VEGF in others, suggesting context-dependent regulation. Histone modifications at VEGF gene loci show disease-specific patterns. MicroRNA regulation of VEGF (miR-200 family, miR-126) is dysregulated in neurodegeneration, with altered expression in neurons, endothelial cells, and glia. These findings suggest that epigenetic modulators targeting VEGF expression may offer therapeutic opportunities.

Mitochondrial Interactions

VEGF signaling intersects with mitochondrial biology in neurodegeneration[@mitchondria2024]. VEGF maintains mitochondrial function through PGC-1α-mediated mitochondrial biogenesis and preserves mitochondrial membrane potential. In neurodegenerative conditions, impaired VEGF signaling contributes to mitochondrial dysfunction and bioenergetic failure. Conversely, mitochondrial toxins reduce VEGF expression, creating a vicious cycle. Strategies targeting both VEGF signaling and mitochondrial health show promise in preclinical models.

Autophagy Modulation

VEGF influences autophagy, a critical process in neurodegeneration[@autophagy2023]. VEGF-induced AKT activation promotes autophagy through mTOR inhibition, helping clear protein aggregates. VEGF deficiency leads to impaired autophagic flux and accumulation of damaged proteins. In models of AD, PD, and ALS, VEGF administration enhances autophagy and reduces pathological protein inclusions. This autophagy modulation represents another mechanism through which VEGF provides neuroprotection.

Future Directions

Personalized Medicine Approaches

Precision medicine for VEGF-based therapies will require biomarker-driven patient selection. Stratification based on VEGF levels, neurovascular unit integrity markers, genetic variants in VEGF pathway genes, and neuroimaging findings will enable targeted intervention. Patients with evidence of VEGF deficiency and neurovascular dysfunction may benefit most from VEGF enhancement, while those with compensatory VEGF elevation may require alternative approaches.

Combination Therapies

Given the complexity of neurodegenerative diseases, VEGF-targeted approaches will increasingly be combined with other interventions. Promising combinations include VEGF with anti-amyloid therapies, tau-targeted treatments, neurotrophic factors, and cellular therapies. Understanding the synergies between VEGF and other disease-modifying approaches will be critical for optimal therapeutic development.

Prevention and Early Intervention

The role of VEGF in early disease stages suggests potential for prevention strategies. Individuals at risk for AD or PD may benefit from lifestyle interventions that enhance VEGF signaling, including exercise, dietary approaches, and vascular risk factor management. Early VEGF modulation before significant neurodegeneration occurs may provide maximal benefit.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References